Management of Lithium in Pregnant Bipolar I Patient
Continue lithium throughout pregnancy with dose adjustments and close monitoring, as the teratogenic risk is lower than previously thought and substantially outweighed by the high risk of bipolar relapse if lithium is discontinued. 1
Key Management Strategy
The FDA label warns that lithium may cause fetal harm, particularly cardiac anomalies including Ebstein's anomaly, and historically recommended withdrawal during the first trimester 1. However, recent evidence shows the actual risk of congenital malformations is much lower than previously reported, and discontinuing lithium poses a greater danger to both mother and fetus through bipolar relapse 2, 3.
Specific Clinical Algorithm:
First Trimester:
- Continue lithium - Recent large studies confirm only a small increased risk of cardiac malformations, far lower than historical estimates 2, 3
- The risk of severe psychiatric relapse (which threatens both maternal and fetal wellbeing) exceeds the teratogenic risk
- Schedule high-resolution fetal anomaly ultrasound at 20 weeks 2
Throughout Pregnancy - Dose Management:
- Expect to increase lithium dose by approximately 50% by third trimester to maintain therapeutic levels 4
- Lithium clearance increases by an average of 63.5% by third trimester due to increased glomerular filtration rate 5
- Dose-adjusted serum concentrations decline by 34% in third trimester compared to baseline 4
Monitoring Protocol:
- Check lithium levels weekly in the third trimester (not just monthly as in non-pregnant patients) 2
- Target therapeutic range: 0.6-1.2 mEq/L 1
- Monitor for mood symptoms - worsening correlates with declining serum levels 5
Delivery Planning:
- Reduce lithium dose to pre-pregnancy levels immediately at delivery onset to prevent postpartum toxicity 2
- Lithium clearance returns to baseline at 4-9 weeks postpartum 5
- Deliver at a specialized hospital with psychiatric, obstetric, and neonatal monitoring capabilities 2
Postpartum Period:
- If lithium was discontinued during pregnancy, restart immediately after delivery 2
- Use high target therapeutic lithium levels - the postpartum period carries extremely high relapse risk (>50% without prophylaxis) 6
- Risk of relapse is more than twofold lower with adequate pharmacological prophylaxis 6
Critical Pitfalls to Avoid
Do not taper lithium in first trimester based on outdated teratogenicity data - This practice stems from older registry data suggesting high Ebstein's anomaly risk, but recent large population studies show much lower actual risk 3. The psychiatric consequences of lithium discontinuation are severe and well-documented 7.
Do not use standard non-pregnant dosing throughout pregnancy - Failure to increase doses as pregnancy progresses leads to subtherapeutic levels and breakthrough mood episodes 5, 4. Individual variability exists, making frequent monitoring essential.
Do not forget to reduce dose at delivery - Maintaining third-trimester doses postpartum causes lithium toxicity as renal clearance rapidly normalizes 5.
Evidence Quality Considerations
The FDA label 1 reflects older data and takes a more cautious stance. However, the most recent and highest quality evidence from 2018-2019 systematic reviews 2, 3 demonstrates that lithium remains highly effective for lithium-responsive bipolar patients during pregnancy, with lower teratogenic risks than historically reported. A 2016 prospective study 7 specifically showed excellent prophylactic efficacy in lithium-responsive women who continued treatment throughout the perinatal period.
Lithium remains the gold standard treatment for bipolar I disorder 6, 8, and for women already stabilized on lithium, continuation with appropriate monitoring provides better maternal and fetal outcomes than switching medications or discontinuing treatment entirely.